Is Amgen Stock Underperforming the Nasdaq?

Core Insights - Amgen Inc. is a leading biopharmaceutical company with a market capitalization of approximately $180 billion, making it one of the largest biotech firms globally [1][2] Stock Performance - Amgen's shares have decreased by 3.3% from the 52-week high of $345.84, reached on November 13 [3] - Over the past three months, AMGN stock has increased by roughly 13.8%, outperforming the NASDAQ Composite, which gained 6.2% during the same period [3] - In the longer term, AMGN stock has gained 13.5% over the past 52 weeks and 28.3% year-to-date (YTD) [4] - The NASDAQ Composite has risen 20% over the same 52-week period and 18.4% YTD [4] - AMGN stock has shown significant momentum, trading above the 50-day and 200-day moving averages since early October [4] Financial Performance - The strong Q3 2025 earnings report, released on November 4, showed revenues increasing by 12% year-over-year (YoY) to $9.6 billion, driven by double-digit sales growth across 16 key products [5] - The growing demand for newer medicines such as Repatha, Tezspire, Evenity, and other rare disease drugs has contributed to the top-line strength [5] - Non-GAAP EPS increased by 1% YoY to $5.64 [5] Competitive Landscape - In contrast, rival Bristol-Myers Squibb Company has seen a pullback of 18.9% over the past 52 weeks and a decline of 15.6% YTD, significantly lagging behind Amgen's performance [6] - Amgen stock has a consensus rating of "Moderate Buy" from 32 analysts, surpassing the mean price target of $325.04 [6]